jRCT2041240115招募中不适用
33-506 :Special Drug Use-Results Survey of OPDIVO (Unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
- 主要终点
- Comprehensive improvement
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •Patients with unresectable advanced or recurrent malignant epithelial tumors excluding squamous cell carcinoma, who have recieved OPDIVO for the first time
排除标准
- •Patients who have received OPDIVO previously
结局指标
主要结局
Comprehensive improvement
时间窗: 6 months after the initiation of OPDIVO or by the end or discontinuation of the treatment
the best antitumor efficacy (RECIST) for 6 months after the initiation of OPDIVO or by the end or discontinuation of the treatment
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
33-505 : Special Drug Use-Results Survey of OPDIVOjRCT2031240473Ono Pharmaceutical Co.,LTD20
已完成
Unknown
Special Drug Use-Results Survey of OPDIVO (classical Hodgkin's lymphoma)classical Hodgkin's lymphomaJPRN-jRCT1080224013ONO PHARMACEUTICAL CO.,LTD.250
已完成
Unknown
Special Drug Use-Results Survey of OPDIVO (NSCLC)non-small cell lung cancerJPRN-jRCT1080223216ONO PHARMACEUTICAL CO., LTD.1,000
已完成
Unknown
Special Drug Use-Results Survey of OPDIVO (RCC)Renal Cell CancerJPRN-jRCT1080224010ONO PHARMACEUTICAL CO.,LTD.500
进行中（未招募）
不适用
33-105 : Drug Use-Results Survey of OPDIVOjRCT2041240121Ono Pharmaceutical Co.,LTD100